Home » Newsletters » BioWorld Science

BioWorld Science

March 4, 2004

View Archived Issues

Complementary effects of rosiglitazone and metformin in type 2 diabetes

Johnson & Johnson to acquire Merck's stake in European nonRx joint venture

New round of financing at Igeneon to advance lead candidates

Nautilus develops enhanced IFNbeta molecules for multiple sclerosis

New data support benefit of Namenda for Alzheimer's

Results from two HspE7 trials

Positive phase I/II results for NicVAX

Regeneron to test IL-1 Trap in phase IIb study

NOP World Heath report on Symbyax

Cell Therapeutics strengthens late-stage development product pipeline

Antisoma continues to acquire new products and advance existing programs

Solifenacin reported both safe and effective in overactive bladder

MDM2 directly suppresses p21: broader anticancer activity for antisense MDM2 inhibitors

Orchid scientists develop new COX inhibitors

Novel 5-HT2A receptor antagonists and their use covered by Biovitrum patent

Janssen researchers present NADPH oxidase inhibitors for arthritis and AD

Aventis describes three novel series of NHE-1 inhibitors

New protein kinase inhibitors for cancer and other disorders discovered at Janssen

New 5-HT6 receptor ligands prepared and tested at Wyeth

Targacept claims new nAChR modulators with utility in pain and CNS disorders

New PDE4 inhibitors with utility in cognition disorders identified at Memory Pharmaceuticals

Lilly to advance LY-519818 into registrational studies

Endpoint met in phase IIa study of DMI-7958

Compugen discovers novel soluble CD40 protein

Myfortic receives FDA approval

ARH-460-16-2 set to enter clinic early next year

Abbott and Millennium identify melanocortin receptor antagonist for disease-associated weight loss

H3 Pharma submits Sanvar IR NDA

Novel CDK inhibitor with in vitro antiapoptotic activity described

Strathclyde Institute for Drug Research seeks support for development of restenosis treatment

Novel anticonvulsant, YM-928, effective in generalized seizure models

Protective effects of brain-derived neurotrophic factor enhanced with RS-0466

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...